ATOS — ATOSSA THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About ATOSSA THERAPEUTICS INC (ATOS)
ATOSSA THERAPEUTICS INC (ATOS) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $733,292. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ATOS
How many top investors track ATOS
A small number of top investors own this.
ATOS Ownership Composition
How ATOSSA THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other97.7%
- Hedge Funds2.3%
Tracked investors reporting ATOS
- Izzy EnglanderDec 31, 2025Millennium ManagementShares1.2MValue$733.3K% Portfolio0.00%
- Ken GriffinDec 31, 2025Citadel AdvisorsShares765.7KValue$451.8K% Portfolio0.00%
- Steve CohenDec 31, 2025Point72 Asset ManagementShares48.1KValue$28.4K% Portfolio0.00%
Recent activity
- $733.3KFeb 17, 2026
- New$28.4KFeb 17, 2026
- New$279.4KNov 14, 2025
Frequently asked questions
- How many institutional investors hold ATOS?
- 3 tracked institutional investors disclosed a position in ATOS (ATOSSA THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of ATOS?
- Izzy Englander, Millennium Management, holds the largest disclosed position in ATOS, valued at $733,292.
- Did institutional ownership of ATOS increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 fully exited ATOS.
- Where does this ATOS ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.